发布时间:
2019
-
07
-
10
点击次数:
0
Positions：
Chief Strategy Officer
Company：
Deuracor Therapeutics, Inc.
个人简介：
Dr. Bin Shi （石斌）joins a startup in August 2018 serving as VP and Chief Strategy Officer for Biology and Business Development functional areas. Previously, Bin worked for Amgen, serving as Head of External R&D and Licensing of Amgen Asia R&D Center (2016 - 2018) to leverage wide external scientific and technology expertise in China and Asian Pacific areas to advance and complement Amgen’s global internal effort in discovery of breakthrough medicines. Before that, Bin worked in Merck and Schering-Plough (1998-2016), overseeing anti-cancer, anti-viral, neuroscience, and vaccine drug discovery and development. Bin has published more than 40 papers, abstracts and patents in reputed journals including JBC, Cancer Research etc, serving as the first and corresponding author, serving as an invited reviewer for eight peer reviewed journals, editorial board member and an invited speaker and meeting chairman at several conferences. She is an invited Industry Mentor by ShanghaiTech Univ. and Nankai Univ. Bin is a lifetime SAPA member, and served as President (2016-2017) in SAPA-GP; a member of BayHelix; an active member of AACR. Bin completed her Ph.D. at Thomas Jefferson University in Philadelphia, her Master of Science degree at State University of New York (SUNY) in Syracuse, and her Bachelor of Science degree at Nankai University in Tianjin China.